iTeos Therapeutics, Inc.

NasdaqGM ITOS

iTeos Therapeutics, Inc. Operating Income Margin for the Trailing 12 Months (TTM) ending September 30, 2024

iTeos Therapeutics, Inc. Operating Income Margin is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.

iTeos Therapeutics, Inc. Operating Income Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was -140.52%, a -297.95% change year over year.
iTeos Therapeutics, Inc. Operating Income Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was 70.99%, a 350.29% change year over year.
iTeos Therapeutics, Inc. Operating Income Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was 15.77%.

Key data

Date	Operating Income Margin	EBT Margin	Net Income Margin	EBITDA Margin

NasdaqGM: ITOS

iTeos Therapeutics, Inc.

CEO	Dr. Michel Detheux Ph.D.
IPO Date	July 24, 2020
Location	United States
Headquarters	321 Arsenal Street
Employees	157
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

Key trends

Past 5 years